spread
highli
pathogen
avian
influenza
among
poultri
migratori
bird
transmiss
human
be
sinc
prompt
concern
next
influenza
pandem
immin
vaccin
princip
strategi
combat
pandem
influenza
howev
pandem
creat
huge
surg
vaccin
demand
although
annual
influenza
vaccin
product
wellplan
process
rapid
bulk
manufactur
avian
influenza
vaccin
unknown
growth
process
characterist
may
challeng
new
approach
immunis
strategi
may
requir
optimis
protect
immunolog
unprim
individu
nov
held
meet
review
progress
develop
vaccin
pandem
influenza
clinician
scientist
manufactur
regul
present
plan
product
evalu
safeti
immunogen
licens
vaccin
pandem
influenza
present
summari
discuss
meet
highli
pathogen
avian
influenza
virus
manipul
revers
genet
produc
virus
retain
origin
viru
novel
surfac
antigen
nonpathogen
suitabl
bulk
product
vaccin
revers
genet
system
well
establish
number
whoaffili
laboratori
reliabl
manipul
virus
howev
experi
influenza
subtyp
limit
may
less
success
releas
high
biocontain
reassort
virus
deriv
revers
genet
highli
pathogen
avian
influenza
virus
must
undergo
stringent
safeti
test
current
take
week
follow
receipt
wildtyp
viru
releas
safe
refer
vaccin
viru
manufactur
countri
guidelin
govern
genet
modifi
organ
impos
addit
regul
work
virus
gener
revers
genet
time
could
reduc
substanti
regulatori
author
agre
allow
releas
virus
earlier
process
intellectu
properti
right
surround
technolog
vaccin
manufactur
may
need
obtain
appropri
licenc
advanc
reduc
delay
develop
refer
virus
essenti
avian
influenza
isol
poultri
human
be
share
quickli
laboratori
antigen
characteris
european
medicin
agenc
us
feder
drug
administr
recognis
approv
pandem
influenza
vaccin
may
grant
earli
phase
evolv
pandem
european
approach
develop
core
dossier
contain
preclin
safeti
data
pertin
exist
influenza
vaccin
dossier
submit
advanc
strain
subtyp
variat
ad
pandem
strain
known
safeti
immunogen
assess
adjuv
new
formul
done
interpandem
period
sinc
fasttrack
approv
must
compromis
safeti
robust
postmarket
surveil
must
integr
part
licens
procedur
follow
first
outbreak
among
human
be
hong
kong
two
dose
convent
surfaceantigen
vaccin
found
poorli
immunogen
unprim
human
be
addit
adjuv
substanti
boost
immun
respons
induc
crossreact
antibodi
antigen
unrel
strain
revers
genet
subunit
vaccin
base
produc
sanofi
pasteur
use
regular
product
process
assess
randomis
trial
among
healthi
adult
usa
addit
studi
underway
children
elderli
adult
earli
analysi
indic
although
vaccin
well
toler
immun
respons
induc
higher
dose
recipi
seroconvert
neutralis
antibodi
two
dose
contain
antigen
respect
clear
data
dosespar
formul
urgent
need
hungarian
investig
omnivest
budapest
aluminium
phosphat
adjuv
wholevirion
vaccin
report
promis
result
singl
dose
contain
antigen
induc
seroconvers
haemagglutinin
inhibit
recipi
assess
date
larger
studi
underway
alum
adjuv
wide
avail
combin
whole
viru
vaccin
allow
eightfold
reduct
antigen
content
maintain
immunogen
randomis
trial
plain
alumadjuv
reversegenet
vaccin
underway
franc
australia
data
analysi
expect
earli
live
attenu
influenza
vaccin
protect
anim
model
may
advantag
induc
humor
mucos
immun
earli
result
clinic
evalu
live
attenu
candid
suggest
recipi
develop
serum
antibodi
two
dose
final
clinic
evalu
dosespar
adjuv
vaccin
formul
urgent
requir
provid
inform
optimis
antigen
use
futur
studi
adjuv
vaccin
contain
nonadjuv
compar
arm
compar
lead
formul
headtohead
studi
wherev
possibl
serum
sampl
vaccin
recipi
store
crossreact
emerg
variant
strain
explor
futur
studi
intern
cooper
requir
success
control
sever
acut
respiratori
syndrom
epidem
maintain
plan
influenza
pandem
clinic
studi
underway
provid
import
inform
rationalis
immunis
strategi
pandem
influenza
review
addit
data
avail
